Physician profile
Manish Arora
NPI 1669500708
$3,569.80
in general payments reported to CMS, 2019-2025
25 companies · $49.86 in 2025
The $49.86 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $326 · 2021: $915 · 2022: $898 · 2023: $718 · 2024: $466 · 2025: $49.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $25.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.29 |
| Education | $25.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.58 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $668.74 | 2021-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $279.69 | 2020-2024 | |
| Janssen Biotech, INC. | $164.84 | 2020-2022 | |
| Braintree Laboratories, INC. | $147.73 | 2021-2024 | Suflave, Sutab |
| Grifols USA, LLC | $141.73 | 2019 | |
| Ferring Pharmaceuticals INC. | $135.48 | 2021-2025 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $109.49 | 2021-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $83.48 | 2020-2024 | Linzess |
| Daiichi Sankyo INC. | $70.58 | 2020 | |
| Pfizer INC. | $51.69 | 2022 | |
| Evoke Pharma, INC. | $39.20 | 2023 | Gimoti |
| Ardelyx, INC. | $36.03 | 2022-2023 | Ibsrela |
| Allergan, INC. | $29.47 | 2020 | |
| Genzyme Corporation | $26.39 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $25.64 | 2024 | Zymfentra |
| Mylan Institutional INC. | $21.46 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $21.18 | 2021 | |
| Pentax of America, INC. | $17.50 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.43 | 2024 | Voquezna |
| Celgene Corporation | $15.76 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $15.72 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.13 | 2023 | Seglentis |
| Boston Scientific Corporation | $13.40 | 2019 | |
| Intra-Sana Laboratories | $4.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.